EVerZom

📍 Paris, France🗓 Founded 2019👥 20 employees💰 Last funded Jul 2025
Biotechnology🌐 everzom.com
Website LinkedIn
EverZom is an exosome biotech company developing treatments for digestive tissue healing like Crohns fistula and organ regeneration like the kidney and the liver. Founded in 2019, EverZom is positioned to become the leader of exosome therapeutics, the next wave of innovation for the biotech industry. Exosomes, small vesicles secreted by cells, are increasingly recognized as potent agents for intercellular communication and play a crucial role to treat a wide range of diseases. Winner of the European EIC Accelerator Program, EVerZom aims to be the upcoming pioneer in this new field. The company has successfully developed a multi-patented platform which enables exosome sourcing, generation, loading, and formulation to create proprietary programs and establish early-stage partnerships in the field of regenerative therapy and oncology.
3
Total investors
0
Early stage
0
Mid stage
3
Late stage
2019
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
3
Frequently asked questions
Who invested in EVerZom?
EVerZom has 3 investors on record on gritt.io and 3 late-stage investors.
When did EVerZom last raise funding?
The most recent investment in EVerZom recorded on gritt.io was in July 2025.
When was EVerZom founded?
EVerZom was founded in 2019.
What industry is EVerZom in?
EVerZom operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is EVerZom based?
EVerZom is headquartered in Paris, France.